NRx Pharmaceuticals announces underwritten public offering of common stock

NRx Pharmaceuticals announced a proposed underwritten public offering of common stock with BTIG and Lucid Capital Markets as lead bookrunners. The company intends to use net proceeds for working capital and general corporate purposes to support growth.